In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.57% change from the preceding trading day.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Shares of Hims & Hers Health ( HIMS 12.82%) surged on Tuesday, closing the session up 5.25% after having been up by as much ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...